The short answer
No final change has taken effect. Cannabis and delta-9 THC remain Schedule I under the Controlled Substances Act, and that is still the federal baseline. The Drug Enforcement Administration did publish a proposed rule in May 2024 that would move marijuana to Schedule III, after the Department of Health and Human Services recommended it. That proposal opened a formal rulemaking and a hearing process that has run slowly. Until a final rule appears in the Federal Register, nothing has changed for a shop, a consumer, or a bank.
cannabis rescheduling update news
What Schedule I controls right now
Schedule I is the tightest tier in the CSA. It is reserved for substances the federal government says have no accepted medical use and a high potential for abuse. The statute lists tetrahydrocannabinols there, with marijuana alongside it. Three practical effects follow. Research stalls because approved supply channels are narrow. Taxes bite because Section 280E blocks normal business deductions for companies that touch a Schedule I drug. Banking gets awkward, since federally insured institutions stay cautious. State legalization never touched any of that.
What a move to Schedule III would change
Schedule III covers drugs such as ketamine, anabolic steroids, and codeine combinations. The definition: accepted medical use, moderate or low physical dependence. For cannabis operators, the headline is tax relief under 280E. Research gets easier to run and fund. Banks and payment processors gain room to work with licensed businesses.
What it would not change
- It would not legalize recreational sales nationwide. Federal possession rules would loosen, but state licenses, local zoning, and age limits stay where they are.
- It would not create interstate commerce in cannabis. That takes an act of Congress, not a scheduling decision.
- It would not turn dispensary flower into an FDA-approved medicine. FDA approval is a separate path that no plant material has cleared.
- It would not settle the THC isomers question on its own. Delta-8, delta-10, and THCA each sit in a gray zone that state legislatures are filling.
Where hemp and the 0.3% line fit
THC's legal status depends on its source. The 2018 Farm Bill pulled hemp out of the CSA definition of marijuana, drawing the line at 0.3% delta-9 THC on a dry weight basis. That one sentence built the legal delta-8, THCA flower, and THC beverage market. Congress has spent recent sessions arguing over whether to rewrite it, with proposals that would count total THC or ban intoxicating hemp products outright. States are not waiting. Several already cap hemp-derived THC by milligram per package, and a few ban it. The schedule question and the hemp question are now separate tracks, and the second one moves faster.
cannabis rescheduling update news
How the rulemaking actually proceeds
After HHS sent its recommendation in 2023, DEA published the proposed rule and took public comment. Opponents challenged the scientific basis, so DEA sent the matter to an administrative law judge for a hearing. That judge takes testimony and issues a recommendation, which the DEA Administrator can accept, reject, or modify. Only then does a final rule get published, and it usually carries a compliance date. Lawsuits remain a real possibility at either end. This is why headlines about rescheduling have outrun the paperwork.
What I watch instead of headlines
- The Federal Register. A final rule shows up there before it shows up in a press release.
- The docket. Hearing transcripts and briefs tell you how strong each side is.
- Congress. A hemp rewrite or a standalone cannabis bill can change the picture faster than administrative review.
For anyone shopping in a legal state, the practical answer today is simple. Buy from a licensed retailer, read the label, and know that state law, not federal scheduling, governs the shelf in front of you.